- $218.54m
- -$229.34m
- 35
- 47
- 45
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.48 | ||
| Price to Tang. Book | 0.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -68.08% | ||
| Return on Equity | -44.54% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 1st, 2020
- Public Since
- May 5th, 2023
- No. of Shareholders
- 17
- No. of Employees
- 83
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 100,709,853
- Address
- 4149 Liberty Canyon Rd., AGOURA HILLS, 91301
- Web
- https://www.acelyrin.com/
- Phone
- +1 8054564393
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SLRN
Q1 2025 ACELYRIN Inc Earnings Release
ACELYRIN Inc Annual Shareholders Meeting
Q2 2025 ACELYRIN Inc Earnings Release
Similar to SLRN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Acelyrin share price?
As of Today at 19:03 UTC, shares in Acelyrin are trading at $2.17. This share price information is delayed by 15 minutes.
How has the Acelyrin share price performed this year?
Shares in Acelyrin last closed at $2.17 and the price had moved by -48.82% over the past 365 days. In terms of relative price strength the Acelyrin share price has underperformed the S&P500 Index by -52.76% over the past year.
What are the analyst and broker recommendations for Acelyrin?
The overall consensus recommendation for Acelyrin is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Acelyrin dividend yield?
Acelyrin does not currently pay a dividend.
Does Acelyrin pay a dividend?
Acelyrin does not currently pay a dividend.
When does Acelyrin next pay dividends?
Acelyrin does not currently pay a dividend.
How do I buy Acelyrin shares?
To buy shares in Acelyrin you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acelyrin?
As of the previous close price of $2.17, shares in Acelyrin had a market capitalisation of $218.54m.
Where are Acelyrin shares listed?
Here are the trading details for Acelyrin:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SLRN
What kind of share is Acelyrin?
Based on an overall assessment of its quality, value and momentum Acelyrin is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acelyrin share price forecast for 2025?
The analyst consensus target price for shares in Acelyrin is $8.00. That is 268.66% above the last closing price of $2.17.
Analysts covering Acelyrin currently have a consensus Earnings Per Share (EPS) forecast of -$2.01 for the next financial year.
Find out moreWhat is the trend in the Acelyrin share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acelyrin. Over the past six months, its share price has underperformed the S&P500 Index by -61.69%.
As of the last closing price of $2.17, shares in Acelyrin were trading -45.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acelyrin PE Ratio?
The Acelyrin PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acelyrin?
We do not have data on Acelyrin's directors